EEG controlled rapid opioid withdrawal under general anaesthesia.
We performed rapid opioid detoxification under propofol anaesthesia in 30 opioid addicts, using the opioid receptor antagonist naltrexone. Two strategies to obtain a sufficient depth of anaesthesia and to avoid anaesthetic overdose were evaluated. Patients were allocated randomly to one of two groups. In group 1, the effects of propofol were monitored by observing clinical signs, and in group 2, depth of anaesthesia was controlled using an EEG threshold method. Withdrawal symptoms and post-anaesthetic recovery time were assessed. All patients remained stable and no anaesthetic complications were noted. There were significant differences in the total dose of propofol given (group 1, mean 72 (SD 9) mg kg-1; group 2, 63 (8) mg kg-1; P < 0.01), duration of anaesthesia (318 (53) min vs 309 (42) min; P < 0.05), duration of recovery time (49 (13) min vs 40 (12) min; P < 0.01) and frequency of withdrawal symptoms between groups. In addition, the incidence of side effects was different between groups (62 vs 29 points on a withdrawal symptom scale; P < 0.01). To obtain a sufficient depth of anaesthesia but to avoid inappropriately large doses of anaesthetic, we consider that EEG monitoring is valuable during rapid opioid detoxification.
Hensel
M
M
Department of Anaesthesiology and Intensive Care, University Hospital Charité, Berlin, Germany.
Wolter
S
S
Kox
W J
WJ
D000768:Anesthesia, General; D018686:Anesthetics, Intravenous; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods; D009271:Naltrexone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D015742:Propofol; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control
D018686:Anesthetics, Intravenous; D009292:Narcotic Antagonists; D009271:Naltrexone; D015742:Propofol